🧬 Research Biosamples for Pharmaceutical, Academic and Biotechnology Research – BIOMEDICA CRO Overview 🌍
Modern biomedical research depends on access to high-quality human biosamples and reliable clinical data. Whether scientists are developing novel cancer diagnostics, validating therapeutic targets, investigating immune-mediated diseases, or creating innovative infectious disease tests, research biosamples often represent the critical starting point for discovery.
At BIOMEDICA CRO, we are proud to support pharmaceutical companies, biotechnology innovators, academic institutions, and diagnostic developers by providing ethically sourced research biosamples and associated clinical data. Over the years, biosamples supplied by our team have contributed to multiple international scientific publications covering oncology, immunology, dermatology, epigenetics, respiratory diseases, infectious diseases, and precision medicine.
The value of research biosamples extends far beyond collection and storage. When provided to experienced investigators, human biospecimens become the foundation for discoveries that may ultimately improve patient care worldwide.
Recent scientific publications have highlighted studies where biosamples supplied by BIOMEDICA CRO contributed to important research initiatives conducted by leading organizations, including Novartis, Scancell, Belgian Volition (VolitionRx), Agilent Technologies, Institute of Science Tokyo, Nagoya University, National Institute of Advanced Industrial Science and Technology (AIST), RIKEN (a National Research and Development Agency in Japan), University of Tsukuba, and many other internationally recognized research groups.
Examples include:
🧪🔬 Atopic Dermatitis and Skin Inflammation Research
Novartis researchers utilized skin tissue obtained from patients with Atopic Dermatitis to investigate the role of IL-26 in type 2 skin inflammation. Such studies help improve our understanding of inflammatory pathways and may support the development of future therapeutic strategies.
👉 Read the publication in the Journal of Investigative Dermatology, article titled “IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1β”.
🧪🔬 Cancer Research and Biomarker Discovery
Researchers from Belgian Volition (VolitionRx) published results of advanced epigenetic profiling studies using frozen PBMCs and fresh-frozen human tissues supplied by BIOMEDICA CRO. These biosamples supported validation of novel assays measuring nucleosome and histone modifications, contributing to biomarker discovery in oncology and other diseases.
👉 Read the publication in the Journal of Biological Chemistry, article titled “High-throughput epigenetic profiling immunoassays for accelerated disease research and clinical development”.
🧪🔬 Small Cell Lung Cancer Therapy Development
Scientists from Scancell Ltd investigated a novel antibody-drug conjugate targeting Fucosyl-GM1, a promising therapeutic target for Small Cell Lung Cancer (SCLC). Patient-derived tumor tissues supplied through BIOMEDICA CRO were used to evaluate target expression and support therapeutic development efforts.
👉 Read the publication in the Journal of Translational Medicine, article titled “SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy”.
🧪🔬 Early Cancer Detection Technologies
A multidisciplinary Japanese research consortium explored urinary exosome-derived microRNA signatures for early cancer detection. Human urine biospecimens supplied by BIOMEDICA CRO contributed to studies investigating non-invasive approaches for identifying cancer-associated molecular patterns.
👉 Read the publication in Analytical Chemistry, article titled “Early Cancer Detection via Multi-microRNA Profiling of Urinary Exosomes Captured by Nanowires”.
🧪🔬 Digital Pathology and Precision Oncology
Agilent Technologies incorporated human tumor biospecimens and clinical data supplied by BIOMEDICA CRO into studies evaluating digital pathology solutions for PD-L1 assessment across multiple cancer indications. Accurate biomarker assessment remains critical for modern immuno-oncology.
👉 Read the publication in the Journal for ImmunoTherapy of Cancer (SITC Proceedings), poster titled “Digital Whole Slide Image scoring is equivalent to microscope glass slide scoring for evaluation of PD-L1 expression across multiple tumor indications”.
🧪🔬 COVID-19 Diagnostic Innovation
Researchers from National Institute of Advanced Industrial Science and Technology (AIST), RIKEN (a National Research and Development Agency in Japan), Hokkaido University, and collaborating institutions used human saliva obtained through BIOMEDICA CRO while developing novel methods for SARS-CoV-2 spike protein detection. Such work demonstrates how biosamples contribute directly to advances in diagnostic technologies.
👉 More details can be found in ACS Central Science, article titled “Pseudo-Luciferase Activity of the SARS-CoV-2 Spike Protein for Cypridina Luciferin”.
And more… Stay tuned for upcoming publications. 🚀
These publications represent only a portion of the projects supported by our team. Every year, BIOMEDICA CRO supplies biosamples for studies involving cancer, autoimmune diseases, dermatological disorders, neurological conditions, infectious diseases, rare diseases, and many other therapeutic areas.
🔍 Looking for a Trusted Partner to Purchase Research Biosamples and Clinical Data?
Since 2017, BIOMEDICA CRO has been providing comprehensive biosample procurement and project management services for pharmaceutical companies, biotechnology organizations, diagnostic developers, and academic research groups worldwide, across a wide range of disease areas.
Our support begins long before sample collection. We conduct feasibility assessments, evaluate recruitment potential, communicate directly with hospitals and physicians, and provide detailed project proposals tailored to specific study requirements. Once a project is approved, our team coordinates documentation, ethics compliance, biosample collection, processing, storage, data management, and shipment logistics.
We routinely support projects involving:
- PBMCs (Peripheral Blood Mononuclear Cells)
- Whole blood
- Plasma, buffy coat and serum
- Fresh-frozen tissue
- FFPE tissues
- Saliva
- Urine
- Cerebrospinal fluid (CSF)
- Synovial fluid
- Matched biospecimen collections
- Associated anonymized clinical data
Our inventory currently includes more than 35,000 banked biospecimens representing a broad range of disease indications and donor populations. In addition to inventory samples, we also perform customized prospective collection projects according to sponsor-specific inclusion and exclusion criteria.
✅ Ethics and Quality Remain Our Highest Priorities
All biosamples are collected in accordance with applicable ethical requirements and regulatory standards.
- Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approval is mandatory.
- All subjects provide informed consent prior to participation.
- Clinical data are fully anonymized.
- Human subject protection standards are strictly followed.
- Biosample processing and logistics are performed according to validated procedures.
Our goal is simple: helping to obtain high-quality research biosamples & clinical data efficiently.
Scientific publications are among the strongest indicators that biosamples are being used successfully in real-world research environments. We are honored that human biospecimens supplied by BIOMEDICA CRO continue to contribute to studies conducted by leading pharmaceutical companies, biotechnology innovators, and academic institutions around the world.
🌐 Interested? 🙂 Click here to explore our inventory of 43,000+ banked biospecimens. Use the available filters to find 🔍 the most suitable specimens and share your list with us so we can discuss further options to purchase biosamples.
For instance, our latest post covers our biospecimen inventory and data capabilities in more detail – check it out by clicking here.
📩 Let’s connect! Feel free to email us at office@biomedica-cro.com, and we will gladly help you find the best possible solution to support your research.
🚀 Stay connected! Follow us on LinkedIn to stay updated on the latest advancements, industry news, and great offers in human biospecimen procurement. Let’s drive innovation together and make remarkable discoveries!
